Ainsworth P J, Koscinski D, Fraser B P, Stuart J A
Molecular Diagnostic Laboratory and Cancer Genetics Unit, London Health Sciences Center, and the University of Western Ontario, London, Ontario, Canada.
Clin Genet. 2004 Sep;66(3):183-8. doi: 10.1111/j.0009-9163.2004.00282.x.
Hereditary non-polyposis colorectal cancer (HNPCC) results from inactivating germline mutations in a set of DNA-mismatch-repair genes, of which the most clinically relevant are hMSH2 and hMLH1. Computer-assisted pedigree risk assessment tools are available to assist in the calculation of an individual's likelihood of bearing such a deleterious mutation. One such tool, cancergene version 3.4 (http://www3.utsouthwestern.edu/cancergene) was used to assess the risk of a deleterious mutation in the genes hMSH2 and/or hMLH1 in a series of probands selected from a panel of 67 South-western Ontario kindred previously identified as likely candidates for HNPCC by established clinical criteria. A DNA sample isolated from peripheral blood leukocytes obtained from each of these probands was examined for genomic rearrangement using the multiplex ligation-dependent probe amplification (MLPA) method. Of the individuals calculated to have a risk of >50% of a hMSH2 or hMLH1 gene mutation by the CancerGene risk assessment tool, 69% (9/13) were shown to have a genomic rearrangement resulting in the deletion of one or more exons of one of these two genes. Family cancer histories predictive of a high risk of HNPCC significantly associate with a genomic rearrangement in hMSH2 or hMLH1.
遗传性非息肉病性结直肠癌(HNPCC)是由一组DNA错配修复基因的种系突变失活引起的,其中与临床最相关的是hMSH2和hMLH1。有计算机辅助的家系风险评估工具可用于协助计算个体携带这种有害突变的可能性。其中一种工具,癌症基因版本3.4(http://www3.utsouthwestern.edu/cancergene)被用于评估从安大略省西南部67个家族组成的小组中选出的一系列先证者中hMSH2和/或hMLH1基因发生有害突变的风险,这些家族先前已根据既定临床标准被确定为HNPCC的可能候选者。使用多重连接依赖探针扩增(MLPA)方法对从这些先证者的外周血白细胞中分离出的DNA样本进行基因组重排检测。在通过癌症基因风险评估工具计算出有超过50%的风险发生hMSH2或hMLH1基因突变的个体中,69%(9/13)被证明存在基因组重排,导致这两个基因中的一个基因的一个或多个外显子缺失。预测HNPCC高风险的家族癌症病史与hMSH2或hMLH1中的基因组重排显著相关。